J&J to eliminate 900 sales-related positions

Share this article:

Johnson & Johnson will cut 900 positions at its Ortho-McNeil-Janssen Pharmaceuticals unit by the end of the second quarter.

According to Kara Russell, a J&J spokesperson, the reduction is part of an overarching corporate strategy focused on dealing with a shift in the pharmaceutical landscape—particularly with respect to the way doctors interact with drug companies.

“Physicians have really begun to voice how they would like to receive [product] information, and when and where they'd like to receive it,” said Russell.

The elimination of 900 positions does not necessarily mean that 900 employees will lose their jobs, noted Russell. Some of the positions will be eliminated through attrition and hiring freezes, she said.

The J&J move follows many other pharma restructurings and reorganizations that usually shed jobs. Increased generic competition, coupled with relatively barren pipelines, has spurred consolidation and mergers across the industry.

“We're taking into consideration what is best for our multiple stakeholders,” said Russell.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...